Stay informed with the latest litigation news. Explore now

IP Verse

Shire Human Genetic Therapies competitive analysis

Latest publications and patents of Shire Human Genetic Therapies New

Explore the latest publications and patents granted to Shire Human Genetic Therapies, showcasing their recent innovations and technological advancements.

Last updated on: Sep 12, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Shire Human Genetic Therapies

EP2858679
Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target CellsPatent Maintained As Amended
EP3626258
Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-SulfataseGranted And Under Opposition
EP2970456
May 19, 2021Methods And Compositions For Delivering Mrna Coded AntibodiesGranted And Under Opposition
EP3103469
Dec 9, 2020Cns Delivery Of Therapeutic AgentsGranted And Under Opposition
EP3134506
Aug 7, 2019Methods For Purification Of Messenger RnaGranted And Under Opposition
EP3060303
Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase DeficiencyRevoked
EP3122878
Oct 24, 2018Mrna Therapy For The Treatment Of Ocular DiseasesOpposition Rejected
EP2867245
Sep 12, 2018Purification Of Iduronate-2-SulfataseRevoked
EP2506857
Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic DiseasesRevoked
EP2718269
Jan 31, 2018Cleavable LipidsNo Opposition Filed Within Time Limit

Latest oppositions filed by Shire Human Genetic Therapies

Explore patent oppositions filed by Shire Human Genetic Therapies against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 18, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2708559
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 21, 2018
EP2708558
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 20, 2018
EP2552955
Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 5, 2018

Latest patents of Shire Human Genetic Therapies opposed by its competitors

Explore Shire Human Genetic Therapies's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2858679
Jun 5, 2024Pulmonary Delivery Of Mrna To Non-Lung Target Cells1
EP3626258
Aug 4, 2021Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase1
EP2970456
May 19, 2021Methods And Compositions For Delivering Mrna Coded Antibodies4
EP3103469
Dec 9, 2020Cns Delivery Of Therapeutic Agents1
EP3134506
Aug 7, 2019Methods For Purification Of Messenger Rna2
EP3060303
Nov 14, 2018Mrna Therapy For Argininosuccinate Synthetase Deficiency1
EP3122878
Oct 24, 2018Mrna Therapy For The Treatment Of Ocular Diseases1
EP2867245
Sep 12, 2018Purification Of Iduronate-2-Sulfatase1
EP2506857
Feb 14, 2018Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases2

Latest PTAB cases involving Shire Human Genetic Therapies New

Discover the latest PTAB cases involving Shire Human Genetic Therapies, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 18, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Shire Human Genetic Therapies

IPR2016-00258Nov 25, 2015GREEN CROSSSHIRE HUMAN GENETIC THERAPIESFinal Written Decision

Top competitors of Shire Human Genetic Therapies

Top competitors of Shire Human Genetic Therapies based on patent oppositions.